| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.09. | AstraZeneca: IMFINZI (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial | 739 | Business Wire | First immunotherapy regimen before and after surgery to demonstrate statistically significant and clinically meaningful overall survival improvement in this setting
Positive results from the NIAGARA... ► Artikel lesen | |
| 15.09. | Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo plus Yervoy in Advanced Melanoma | 1.010 | Business Wire | These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for official ESMO press conference At ten years, more than 40% (43%) of... ► Artikel lesen | |
| 15.09. | Veracyte, Inc.: New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer | 512 | Business Wire | Findings are from ancillary study of phase 3 STAMPEDE trial Data support company's plan to expand Decipher Prostate test to patients with metastatic disease Veracyte, Inc. (Nasdaq: VCYT),... ► Artikel lesen | |
| 15.09. | Exelixis, Inc.: Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024 | 509 | Business Wire | Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX) in combination with atezolizumab... ► Artikel lesen | |
| 15.09. | Genmab A/S: Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial | 650 | Business Wire | Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed... ► Artikel lesen | |
| 15.09. | Incyte's CDK2 Inhibitor INCB123667 zeigt vielversprechende Anzeichen von klinischer Wirkung bei Patienten mit soliden Tumoren in fortgeschrittenem Stadium | 533 | Business Wire | Heute wurden auf Incyte-Investorevent neue Daten zur Reaktion auf Bekämpfung von Tumoren bei unterschiedlicher Dosierung und Behandlung präsentiert. Diese Ergebnisse basieren auf Daten... ► Artikel lesen | |
| 15.09. | Research and Markets: Europe Biopesticides and Biofertilizers Market Analysis and 10 Year Forecast 2023-2033: Increasing Usage of Liquid Biofertilizers and Biopesticides as a Sustainable Solution for Agriculture - ResearchAndMarkets.com | 766 | Business Wire | The "Europe Biopesticides and Biofertilizers Market: Focus on Crop Type, Product Type, Source, Formulation, and Country Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| SUPER MICRO COMPUTER | 2.927 |
| EVOTEC | 2.177 |
| TUI | 1.862 |
| BAYER | 1.797 |
| NVIDIA | 1.684 |
| NEL | 1.289 |
| RENK GROUP | 1.151 |
| RHEINMETALL | 1.048 |
| TESLA | 884 |
| PALANTIR TECHNOLOGIES | 834 |
| DEUTSCHE BANK | 782 |
| VOLKSWAGEN | 759 |
| MICROSTRATEGY | 721 |
| BYD | 702 |
| PLUG POWER | 668 |
| COMMERZBANK | 660 |
| BASF | 638 |
| JINKOSOLAR | 619 |
| MERCEDES-BENZ | 596 |
| AMAZON | 580 |
| DEUTSCHE TELEKOM | 556 |
| INTEL | 556 |
| BMW | 550 |
| ALLIANZ | 542 |
| THYSSENKRUPP | 537 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
